Based on the understanding of CaMKII as a pathological signaling molecule in cardiomyopathies, we asked whether an active strategy of chronic myocardial-targeted CaMKII inhibition could prevent or reduce cardiac hypertrophy in a mouse model (Ryr2ADA/ADA mice) with a well-defined mutation in RyR2. Here, RYR2 is linked to cardiac hypertrophy.